Review and recommendations on the current practice of meta-analyses: A guide to appraise the evidence

EuroIntervention

Volumn 9, Issue 9, 2014, Pages 1013-1020

  Osnabrugge, Ruben L ^a   Capodanno, Davide ^b   Cummins, Paul ^c   Kappetein, A Pieter ^a   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Ferrarotto Hospital   (Italy)

^c EuroIntervention   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB;

ACUTE CORONARY SYNDROME; CARDIOLOGY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; EDITORIAL; EFFECT SIZE; LEFT CORONARY ARTERY; META ANALYSIS (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; HUMANS; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STATISTICS AS TOPIC;

EID: 84893361983     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV9I9A172     Document Type: Editorial

References (53)

1. Davidoff F, Haynes B, Sackett D, Smith R. Evidence based medicine. BMJ. 1995;310:1085-6.
2. Siontis KC, Hernandez-Boussard T, Ioannidis JP. Overlapping meta-analyses on the same topic: survey of published studies. BMJ. 2013;347:f4501.
3. Bastian H, Glasziou P, Chalmers I. Seventy-five trials and eleven systematic reviews a day: how will we ever keep up? PLoS Med. 2010;7:e1000326.
4. Moher D. The problem of duplicate systematic reviews. BMJ. 2013;347:f5040.
5. Hansen PR, Iversen A, Abdulla J. Improved clinical outcomes with intracoronary compared to intravenous abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a systematic review and meta-analysis. J Invasive Cardiol. 2010;22:278-82.
6. De Luca G, Verdoia M, Suryapranata H. Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials. Atherosclerosis. 2012;222:426-33.
7. Navarese EP, Kozinski M, Obonska K, Margheri M, Gurbel PA, Kubica J, De Luca G. Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials. Platelets. 2012;23:274-81.
8. Shimada YJ, Nakra NC, Fox JT, Kanei Y. Meta-analysis of prospective randomized controlled trials comparing intracoronary versus intravenous abciximab in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol. 2012;109:624-8.
9. De Rosa S, Caiazzo G, Torella D, Indolfi C. Intracoronary abciximab reduces death and major adverse cardiovascular events in acute coronary syndromes: a meta-analysis of clinical trials. Int J Cardiol. 2013;168:1298-305.
10. Kubica J, Koziński M, Navarese EP, Tantry US, Grześk G, Fabiszak T, Kubica A, Świa̧tkiewicz I, Bliden KP, Gurbel PA. Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials. Cardiol J. 2012;19:230-42.
11. Wang JN, Diao S, Tang YJ, Hou AJ, Yuan HB, Zheng Y, Zhou YH. Intracoronary versus intravenous administration of abciximab in patients with acute coronary syndrome: a meta-analysis. PloS One. 2013;8:e58077.
12. Piccolo R, Eitel I, Iversen A, Gu Y, Dominguez-Rodriguez A, De Smet B, Mahmoud K, Abreu-Gonzales P, Thiele H, Piscione F. Intracoronary versus intravenous bolus abciximab administration in patients undergoing primary percutaneous coronary intervention with acute ST-elevation myocardial infarction: a pooled analysis of individual patient data from 5 randomized controlled trials. EuroIntervention. 2014;9:1111-21.
13. Biondi-Zoccai GG, Lotrionte M, Moretti C, Meliga E, Agostoni P, Valgimigli M, Migliorini A, Antoniucci D, Carrié D, Sangiorgi G, Chieffo A, Colombo A, Price MJ, Teirstein PS, Christiansen EH, Abbate A, Testa L, Gunn JP, Burzotta F, Laudito A, Trevi GP, Sheiban I. A collaborative systematic review and meta-analysis on 1278 patients undergoing percutaneous drug-eluting stenting for unprotected left main coronary artery disease. Am Heart J. 2008;155:274-83.
14. Naik H, White AJ, Chakravarty T, Forrester J, Fontana G, Kar S, Shah PK, Weiss RE, Makkar R. A meta-analysis of 3,773 patients treated with percutaneous coronary intervention or surgery for unprotected left main coronary artery stenosis. JACC Cardiovasc Interv. 2009;2:739-47.
15. Capodanno D, Stone GW, Morice MC, Bass TA, Tamburino C. Percutaneous coronary intervention versus coronary artery bypass graft surgery in left main coronary artery disease: a meta-analysis of randomized clinical data. J Am Coll Cardiol. 2011;58:1426-32.
16. Ferrante G, Presbitero P, Valgimigli M, Morice MC, Pagnotta P, Belli G, Corrada E, Onuma Y, Barlis P, Locca D, Eeckhout E, Di Mario C, Serruys PW. Percutaneous coronary intervention versus bypass surgery for left main coronary artery disease: a meta-analysis of randomised trials. EuroIntervention. 2011;7:738-46.
17. Kajimoto K, Miyauchi K, Yamamoto T, Daida H, Amano A. Meta-analysis of randomized controlled trials on the treatment of unprotected left main coronary artery disease: one-year outcomes with coronary artery bypass grafting versus percutaneous coronary artery intervention with drug-eluting stent. J Card Surg. 2012;27:152-7.
18. Lee MS, Yang T, Dhoot J, Liao H. Meta-analysis of clinical studies comparing coronary artery bypass grafting with percutaneous coronary intervention and drug-eluting stents in patients with unprotected left main coronary artery narrowings. Am J Cardiol. 2010;105:1070-5.
19. Alam M, Huang HD, Shahzad SA, Kar B, Virani SS, Rogers PA, Paniagua D, Bozkurt B, Palacios I, Kleiman NS, Jneid H. Percutaneous coronary intervention vs. coronary artery bypass graft surgery for unprotected left main coronary artery disease in the drug-eluting stents era - an aggregate data meta-analysis of 11,148 patients. Circ J. 2013;77:372-82.
20. Gao F, Zhou YJ, Shen H, Wang ZJ, Yang SW, Liu XL. Metaanalysis of percutaneous coronary intervention versus coronary artery bypass graft surgery in patients with diabetes and left main and/or multivessel coronary artery disease. Acta Diabetol. 2013;50:765-73.
21. Jang JS, Choi KN, Jin HY, Seo JS, Yang TH, Kim DK, Kim DS, Urm SH, Chun JH, Kang SJ, Park DW, Lee SW, Kim YH, Lee CW, Park SW, Park SJ. Meta-analysis of three randomized trials and nine observational studies comparing drug-eluting stents versus coronary artery bypass grafting for unprotected left main coronary artery disease. Am J Cardiol. 2012;110:1411-8.
22. Desch S, Boudriot E, Rastan A, Buszman PE, Bochenek A, Mohr FW, Schuler G, Thiele H. Bypass surgery versus percutaneous coronary intervention for the treatment of unprotected left main disease. A meta-analysis of randomized controlled trials. Herz. 2013;38:48-56.
23. Sá MP, Soares AM, Lustosa PC, Martins WN, Browne F, Ferraz PE, Vasconcelos FP, Lima RC. Meta-analysis of 5,674 patients treated with percutaneous coronary intervention and drug-eluting stents or coronary artery bypass graft surgery for unprotected left main coronary artery stenosis. Eur J Cardiothorac Surg. 2013;43:73-80.
24. Bittl JA, He Y, Jacobs AK, Yancy CW, Normand SL. Bayesian methods affirm the use of percutaneous coronary intervention to improve survival in patients with unprotected left main coronary artery disease. Circulation. 2013;127:2177-85.
25. Shrier I, Boivin JF, Platt RW, Steele RJ, Brophy JM, Carnevale F, Eisenberg MJ, Furlan A, Kakuma R, Macdonald ME, Pilote L, Rossignol M. The interpretation of systematic reviews with meta-analyses: an objective or subjective process? BMC Med Inform Decis Mak. 2008;8:19.
26. Jadad AR, Cook DJ, Browman GP. A guide to interpreting discordant systematic reviews. CMAJ. 1997;156:1411-6.
27. Deeks JJ, Higgins JPT, Altman DG. Analysing Data and Undertaking Meta-Analyses. Cochrane Handbook for Systematic Reviews of Interventions: John Wiley & Sons, Ltd, Chichester, UK; 2008. p.243-96.
28. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
29. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-58.
30. Osnabrugge RL, Kappetein AP, Janssens AC. Carriage of reduced-function CYP2C19 allele among patients treated with clopidogrel. JAMA. 2011;305:467-8.
31. Teramukai S, Matsuyama Y, Mizuno S, Sakamoto J. Individual patient-level and study-level meta-analysis for investigating modifiers of treatment effect. Jpn J Clin Oncol. 2004;34:717-21.
32. Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA. 1990;263:1385-9.
33. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34.
34. Harbord RM, Egger M, Sterne JA. A modified test for smallstudy effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006;25:3443-57.
35. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323:101-5.
36. Oxman AD, Guyatt GH. Validation of an index of the quality of review articles. J Clin Epidemiol. 1991;44:1271-8.
37. Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, Henry DA, Boers M. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol. 2009;62:1013-20.
38. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100.
39. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Metaanalysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-12.
40. Shojania KG, Sampson M, Ansari MT, Ji J, Doucette S, Moher D. How quickly do systematic reviews go out of date? A survival analysis. Ann Intern Med. 2007;147:224-33.
41. Garg S, Sarno G, Girasis C, Vranckx P, de Vries T, Swart M, Bressers M, Garcia-Garcia HM, van Es GA, Räber L, Campo G, Valgimigli M, Dawkins KD, Windecker S, Serruys PW. A patientlevel pooled analysis assessing the impact of the SYNTAX (synergy between percutaneous coronary intervention with taxus and cardiac surgery) score on 1-year clinical outcomes in 6,508 patients enrolled in contemporary coronary stent trials. JACC Cardiovasc Interv. 2011;4:645-53.
42. White HD, Chew DP, Dauerman HL, Mahaffey KW, Gibson CM, Stone GW, Gruberg L, Harrington RA, Bhatt DL. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J. 2012;163:82-90.e4.
43. Sutton AJ, Donegan S, Takwoingi Y, Garner P, Gamble C, Donald A. An encouraging assessment of methods to inform priorities for updating systematic reviews. J Clin Epidemiol. 2009;62:241-51.
44. Tsertsvadze A, Maglione M, Chou R, Garritty C, Coleman C, Lux L, Bass E, Balshem H, Moher D. Updating comparative effectiveness reviews: current efforts in AHRQ's Effective Health Care Program. J Clin Epidemiol. 2011;64:1208-15.
45. Sutton AJ, Abrams KR. Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res. 2001;10:277-303.
46. Goodman SN. Bayesian methods for evidence evaluation: are we there yet? Circulation. 2013;127:2367-9.
47. Booth A, Clarke M, Ghersi D, Moher D, Petticrew M, Stewart L. An international registry of systematic-review protocols. Lancet. 2011;377:108-9.
48. Booth A, Clarke M, Dooley G, Ghersi D, Moher D, Petticrew M, Stewart L. PROSPERO at one year: an evaluation of its utility. Syst Rev. 2013;2:4.
49. Booth A, Clarke M, Dooley G, Ghersi D, Moher D, Petticrew M, Stewart L. The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. Syst Rev. 2012;1:2.
50. Ioannidis JP, Karassa FB. The need to consider the wider agenda in systematic reviews and meta-analyses: breadth, timing, and depth of the evidence. BMJ. 2010;341:c4875.
51. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, Kimura T, Briguori C, Sabatè M, Kim HS, De Waha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;379:1393-402.
52. Ioannidis JP. Integration of evidence from multiple metaanalyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. CMAJ. 2009;181:488-93.
53. Mills EJ, Ioannidis JP, Thorlund K, Schunemann HJ, Puhan MA, Guyatt GH. How to use an article reporting a multiple treatment comparison meta-analysis. JAMA. 2012;308:1246-53.